Compound libraries will be screened at the Michigan High Throughput Screening Center under the direction of Robert Kilkuskie.
The company said that the antibodies developed in this program against tau oligomers will be used for drug development and as biomarkers for drug efficacy during disease progression.
Oligomerix president and CEO James Moe said that recent advances in the field indicate that tau oligomers are involved in alzheimer’s disease progression and inhibit memory formation.
"Reducing tau oligomers with small molecule or antibody therapeutics should halt or reverse the course of alzheimer’s and related neurodegenerative diseases," Moe said.